APA (7th ed.) Citation

Ohtake, A., Abe, Y., Murayama, K., Shiraishi, H., Osaka, H., Kumada, S., . . . Fukuda, K. (2026). A phase III double-blind, placebo-controlled, randomized withdrawal trial of 5‑aminolevulinic acid hydrochloride with sodium ferrous citrate for efficacy and safety in patients diagnosed as Leigh syndrome. PLoS ONE, 21(7), 1. https://doi.org/10.1371/journal.pone.0332283

Chicago Style (17th ed.) Citation

Ohtake, Akira, et al. "A Phase III Double-blind, Placebo-controlled, Randomized Withdrawal Trial of 5‑aminolevulinic Acid Hydrochloride with Sodium Ferrous Citrate for Efficacy and Safety in Patients Diagnosed as Leigh Syndrome." PLoS ONE 21, no. 7 (2026): 1. https://doi.org/10.1371/journal.pone.0332283.

MLA (9th ed.) Citation

Ohtake, Akira, et al. "A Phase III Double-blind, Placebo-controlled, Randomized Withdrawal Trial of 5‑aminolevulinic Acid Hydrochloride with Sodium Ferrous Citrate for Efficacy and Safety in Patients Diagnosed as Leigh Syndrome." PLoS ONE, vol. 21, no. 7, 2026, p. 1, https://doi.org/10.1371/journal.pone.0332283.